News | February 12, 2015

ACC, Symphony Health Solutions Create New Cardiac Research Platform

Platform contains medical history of 5 million anonymized patients

February 12, 2015 – Symphony Health Solutions (SHS) and the American College of Cardiology announced the completion of a new research platform. The HIPAA-compliant platform combines anonymized patient-level data from the ACC's National Cardiovascular Data Registry (NCDR) with SHS's Integrated Dataverse, which includes prescription, medical and hospital claims. The newly integrated data includes approximately 5 million anonymized patients with up to six years of observed diagnoses, procedures, therapies and related findings.

Information from a large set of patients that is both broad in scope and deep in detail has, before now, been difficult to obtain — yet vital to improve care. The creation of a new analytical platform now enables a wide range of new analyses to help achieve that goal. The organizations will use the combined data sources to complete research projects focused on clinical outcomes, comparative effectiveness, therapy adoption and use, and population health, as well as additional studies and projects of interest. These analyses of patterns and treatments can ultimately improve care, enhance outcomes and reduce unnecessary healthcare costs.

"This analytic platform is ground-breaking in the level of data it will provide," said John S. Rumsfeld, M.D., Ph.D., FACC, chief science officer of the American College of Cardiology National Cardiovascular Data Registries. "The partnership between ACC and SHS brings together the detailed clinical data from the registries with the longitudinal data resources of SHS. This creates a synergy that can yield critical insights on improving cardiovascular care and patient outcomes."

Analytics solutions produced through the collaboration will have broad applicability across the healthcare market. Entities such as life sciences organizations and the government, with whom ACC and SHS engage today, will also benefit from the new research offerings.

For more information: or

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init